AG˹ٷ

STOCK TITAN

[Form 4] Northern Trust Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Cardio Diagnostics Holdings Inc. (CDIO) � Form 4 insider filing

Director Peter K. Fung reported the grant of 1,736 stock options on 06/30/2025. Each option carries an exercise price of $3.60 and will expire on 06/30/2035. The filing indicates the transaction code “A,� denoting an acquisition rather than a sale. After this award, Fung directly holds 2,443 derivative securities (stock options) linked to CDIO common stock. No open-market purchases or disposals of common shares were disclosed.

Cardio Diagnostics Holdings Inc. (CDIO) � Comunicazione interna Form 4

Il direttore Peter K. Fung ha riportato la concessione di 1.736 opzioni azionarie il 30/06/2025. Ogni opzione ha un prezzo di esercizio di 3,60 $ e scadrà il 30/06/2035. La comunicazione indica il codice transazione “A,� che rappresenta un'acquisizione e non una vendita. Dopo questo premio, Fung detiene direttamente 2.443 strumenti derivati (opzioni azionarie) collegati alle azioni ordinarie di CDIO. Non sono state segnalate operazioni di acquisto o vendita di azioni ordinarie sul mercato aperto.

Cardio Diagnostics Holdings Inc. (CDIO) � Presentación interna Formulario 4

El director Peter K. Fung informó la concesión de 1,736 opciones sobre acciones el 30/06/2025. Cada opción tiene un precio de ejercicio de $3.60 y expirará el 30/06/2035. La presentación indica el código de transacción “A,� que denota una adquisición en lugar de una venta. Tras esta adjudicación, Fung posee directamente 2,443 valores derivados (opciones sobre acciones) vinculados a las acciones ordinarias de CDIO. No se revelaron compras o ventas de acciones ordinarias en el mercado abierto.

Cardio Diagnostics Holdings Inc. (CDIO) � 내부� 보고� Form 4

이사 Peter K. Fung은 2025� 6� 30일에 1,736� 스톡옵션 부�� 보고했습니다. � 옵션� 행사가격은 $3.60이며 만료일은 2035� 6� 30일입니다. 보고서에� 거래 코드 “A”가 표시되어 있으�, 이는 매도가 아닌 취득� 의미합니�. � 수여 이후 Fung은 CDIO 보통주와 연계� 2,443개의 파생증권(스톡옵션)� 직접 보유하고 있습니다. 공개 시장에서� 보통� 매매� 보고되지 않았습니�.

Cardio Diagnostics Holdings Inc. (CDIO) � Déclaration d’initié Formulaire 4

Le directeur Peter K. Fung a déclaré la cession de 1 736 options d’achat d’actions le 30/06/2025. Chaque option comporte un prix d’exercice de 3,60 $ et expirera le 30/06/2035. La déclaration indique le code de transaction « A », signifiant une acquisition et non une vente. Après cette attribution, Fung détient directement 2 443 titres dérivés (options sur actions) liés aux actions ordinaires de CDIO. Aucun achat ou vente d’actions ordinaires sur le marché libre n’a été divulgué.

Cardio Diagnostics Holdings Inc. (CDIO) � Insider-Meldung Form 4

Direktor Peter K. Fung meldete die Gewährung von 1.736 Aktienoptionen am 30.06.2025. Jede Option hat einen Ausübungspreis von 3,60 $ und läuft am 30.06.2035 ab. Die Meldung weist den Transaktionscode „A� aus, der einen Erwerb und keinen Verkauf kennzeichnet. Nach dieser Zuteilung hält Fung direkt 2.443 derivative Wertpapiere (Aktienoptionen), die mit den Stammaktien von CDIO verbunden sind. Keine Käufe oder Verkäufe von Stammaktien am offenen Markt wurden offengelegt.

Positive
  • Director received 1,736 new stock options at an exercise price of $3.60, raising his derivative stake to 2,443 options
Negative
  • None.

Insights

TL;DR � Routine option grant; modestly positive insider signal, immaterial to fundamentals.

The Form 4 shows a standard equity incentive: 1,736 options at $3.60 awarded to Director Peter K. Fung, increasing his direct derivative position to 2,443. Because this is a grant (code “A�) rather than an open-market purchase, cash outlay is zero and immediate balance-sheet impact negligible. Still, option grants slightly align director incentives with shareholders. No disposition of common shares suggests the director is not reducing exposure. Given the small size of the award and lack of cash transaction, the filing is not materially impactful to CDIO’s valuation but can be read as a neutral-to-positive governance signal.

Cardio Diagnostics Holdings Inc. (CDIO) � Comunicazione interna Form 4

Il direttore Peter K. Fung ha riportato la concessione di 1.736 opzioni azionarie il 30/06/2025. Ogni opzione ha un prezzo di esercizio di 3,60 $ e scadrà il 30/06/2035. La comunicazione indica il codice transazione “A,� che rappresenta un'acquisizione e non una vendita. Dopo questo premio, Fung detiene direttamente 2.443 strumenti derivati (opzioni azionarie) collegati alle azioni ordinarie di CDIO. Non sono state segnalate operazioni di acquisto o vendita di azioni ordinarie sul mercato aperto.

Cardio Diagnostics Holdings Inc. (CDIO) � Presentación interna Formulario 4

El director Peter K. Fung informó la concesión de 1,736 opciones sobre acciones el 30/06/2025. Cada opción tiene un precio de ejercicio de $3.60 y expirará el 30/06/2035. La presentación indica el código de transacción “A,� que denota una adquisición en lugar de una venta. Tras esta adjudicación, Fung posee directamente 2,443 valores derivados (opciones sobre acciones) vinculados a las acciones ordinarias de CDIO. No se revelaron compras o ventas de acciones ordinarias en el mercado abierto.

Cardio Diagnostics Holdings Inc. (CDIO) � 내부� 보고� Form 4

이사 Peter K. Fung은 2025� 6� 30일에 1,736� 스톡옵션 부�� 보고했습니다. � 옵션� 행사가격은 $3.60이며 만료일은 2035� 6� 30일입니다. 보고서에� 거래 코드 “A”가 표시되어 있으�, 이는 매도가 아닌 취득� 의미합니�. � 수여 이후 Fung은 CDIO 보통주와 연계� 2,443개의 파생증권(스톡옵션)� 직접 보유하고 있습니다. 공개 시장에서� 보통� 매매� 보고되지 않았습니�.

Cardio Diagnostics Holdings Inc. (CDIO) � Déclaration d’initié Formulaire 4

Le directeur Peter K. Fung a déclaré la cession de 1 736 options d’achat d’actions le 30/06/2025. Chaque option comporte un prix d’exercice de 3,60 $ et expirera le 30/06/2035. La déclaration indique le code de transaction « A », signifiant une acquisition et non une vente. Après cette attribution, Fung détient directement 2 443 titres dérivés (options sur actions) liés aux actions ordinaires de CDIO. Aucun achat ou vente d’actions ordinaires sur le marché libre n’a été divulgué.

Cardio Diagnostics Holdings Inc. (CDIO) � Insider-Meldung Form 4

Direktor Peter K. Fung meldete die Gewährung von 1.736 Aktienoptionen am 30.06.2025. Jede Option hat einen Ausübungspreis von 3,60 $ und läuft am 30.06.2035 ab. Die Meldung weist den Transaktionscode „A� aus, der einen Erwerb und keinen Verkauf kennzeichnet. Nach dieser Zuteilung hält Fung direkt 2.443 derivative Wertpapiere (Aktienoptionen), die mit den Stammaktien von CDIO verbunden sind. Keine Käufe oder Verkäufe von Stammaktien am offenen Markt wurden offengelegt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Petrino Richard

(Last) (First) (Middle)
50 SOUTH LASALLE STREET

(Street)
CHICAGO IL 60603

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NORTHERN TRUST CORP [ NTRS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2025 A 2.48 A $127.99 2,327(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents stock units payable automatically on a 1-for-1 basis in shares of the Corporation's common stock.
Remarks:
Michael Rouvina, Attorney-in-Fact for Richard Petrino 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CDIO director Peter K. Fung acquire according to the Form 4?

He received 1,736 stock options to buy CDIO common shares.

What is the exercise price and expiration date of the newly granted options?

The options are exercisable at $3.60 per share and expire on 06/30/2035.

How many derivative securities does Fung hold after this transaction?

He directly owns 2,443 stock options following the grant.

Were any common shares of Cardio Diagnostics bought or sold?

No. The filing reports only an option grant; no common stock transactions were disclosed.

When was the transaction and when was the Form 4 filed?

The transaction occurred on 06/30/2025, and the form was signed on 07/02/2024.
Northern Trust

NASDAQ:NTRS

NTRS Rankings

NTRS Latest News

NTRS Latest SEC Filings

NTRS Stock Data

23.92B
192.89M
0.71%
87.64%
1.69%
Asset Management
State Commercial Banks
United States
CHICAGO